Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib DDI Study with CYP3A Inhibitors in B-cell Malignancy
NCT02381080Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of ibrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL) and 3 more (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration of Ibrutinib, Minimum Observed Plasma Concentration of Ibrutinib and 3 more. Started May 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02381080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381080.